Abstract:Neuroblastoma has heterogenous clinical presentations that are reflected by several well-defined clinical factors and biomarkers. Combinations of these clinical and biologic prognostic factors have been used for decades to generate classifiers to stratify patients into risk groups (low, intermediate, and high), which in turn are used to inform and tailor treatment as reported in the new NCCN Clinical Practice Guidelines in Oncology for Neuroblastoma. Risk classification uses clinical features, such as age and tumor stage, along with the most significant prognostic tumor biomarkers, including histologic features (differentiation and mitosis-karyorrhexis index), MYCN amplification status, chromosomal copy number alterations (segmental or numerical), and ploidy (DNA content). Recent next-generation sequencing approaches have identified additional tumor-specific genetic factors that have potential roles as prognostic and predictive biomarkers. These emerging biomarkers include telomerase maintenance mechanisms, such as telomerase reverse transcription (TERT) expression and alternative lengthening of telomeres (ALT) status. Somatic alterations of genes, including mutations in the anaplastic lymphoma kinase gene ALK, detected in >10% of patients with newly diagnosed disease, have both prognostic and predictive roles in determining eligibility for targeted therapies (eg, ALK tyrosine kinase inhibitors). In addition to diagnostic tumor-derived biomarkers, significant effort is being directed toward identification of markers to predict response to chemotherapy and immunotherapies. With the increasing use of GD2-containing immunotherapy regimens, efforts are aimed at identifying host or tumor microenvironment immune correlatives that can serve as predictive biomarkers. Understanding the potential role of liquid biopsies as biomarkers during and following treatment, including sequential circulating tumor DNA or tumor-specific mRNA transcripts, is expected to enhance the ability to predict recurrences and also inform understanding of tumor evolution and therapy resistance. These and other emerging biomarkers will lead to refinement and optimization of future neuroblastoma risk classification systems.

Advances in Liquid Biopsy in Neuroblastoma

Extracellular vesicle derived miRNAs from plasma as promising diagnosis and prognosis biomarkers for neuroblastoma

The Role of Liquid Biopsy in Neuroblastoma: A Scoping Review

Updates on liquid biopsies in neuroblastoma for treatment response, relapse and recurrence assessment

The Role of Liquid Biopsy in Gastroenteropancreatic Neuroendocrine Neoplasms

Liquid biopsy: early and accurate diagnosis of brain tumor

Nanotechnology-Based Diagnostic and Therapeutic Strategies for Neuroblastoma

Liquid Biomarkers for Improved Diagnosis and Classification of CNS Tumors

MicroRNAs in Neuroblastoma: Biomarkers with Therapeutic Potential

Current and Emerging Biomarkers: Impact on Risk Stratification for Neuroblastoma

Liquid biopsy in CNS tumors: Current status & future perspectives

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

The Utility of Liquid Biopsy in Central Nervous System Malignancies

Liquid biopsies in myeloid malignancies

Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives

Single-cell landscape analysis reveals distinct regression trajectories and novel prognostic biomarkers in primary neuroblastoma

Recent advances in liquid biopsy of central nervous system lymphomas: case presentations and review of the literature

Liquid Biopsy Strategies to Distinguish Progression from Pseudoprogression and Radiation Necrosis in Glioblastomas

Advances and Prospects in Liquid Biopsy Techniques for Malignant Tumor Diagnosis and Surveillance

Update on liquid biopsy in clinical management of non-small cell lung cancer

Proteomic analysis of serum small extracellular vesicles identifies diagnostic biomarkers for neuroblastoma